Active

Contract Opportunity

THIS IS A SOURCES SOUGHT (SS) NOTICE ONLY, NOT A SOLICITATION ANNOUNCEMENT AND SHOULD NOT BE CONSIDERED AS SUCH. This Sources Sought Notice is for informational and planning purposes only and shall not be construed as a solicitation or as an obligation or commitment by the Government at this time. This notice is intended strictly for market research. The purpose of this Sources Sought notice is to determine interest and capability and potential qualifications of service-disabled veteran owned small businesses, veteran owned small businesses, and small businesses relative to the North American Industry Classification Code (NAICS) 325412 (Pharmaceutical Preparation Manufacturing).
The Central Arkansas Veterans Health Care System (CAVHCS) will be pursuing a firm fixed price Indefinite Delivery Indefinite Quantity contract (IDIQ) in the near future. The IDIQ contract will be awarded to a single Contractor for a base year and 4, one-year options for radiopharmaceutical supplies.
Potential sources shall submit:
Capabilities and experience for providing this product
Manufacturer
Country of Origin
Business Size (i.e. Small Business, SDVOSB, Woman Owned Small Business etc.)
SAM UEI
Responses to this notice shall be emailed to Tammie Chaney at Tammie.Chaney@va.gov no later than March 5, 2024, at 10:00 am Central Time. Include the following in the email subject line: Radiopharmaceutical Supplies .

Background
Nuclear Medicine requires that all radiopharmaceuticals be delivered within allowable timeframes. There is a very short for most radiopharmaceuticals needed to perform required tests. In addition, this is a highly regulated service and must meet requirements from the Nuclear Regulatory Commission. Samples must be picked up within a specific timeframe, for example, WBC scans must be picked up within one hour of notification and the returned tagged blood within 3 hours of pick-up.
Scope of Work:
The contractor shall provide all resources necessary to accomplish the deliverables described in this statement of work (SOW), except as may otherwise be specified. This shall include delivery of routine orders for next day radiopharmaceuticals by 0630 and delivery within one (1) hour for all urgent or emergent requests for radiopharmaceuticals using the proper transporting protocols and meeting the standard classifications to identify radiation limits established by the Department of Transportation and the Nuclear Regulatory Commission.

General Requirements
1. The contractor shall provide delivery by 0630 a.m. on all routine orders for radiopharmaceuticals and shall provide delivery within 1 hour for all urgent or emergent requests for radiopharmaceuticals.
2. The contractor shall ensure that all deliveries to Central Arkansas Veterans Healthcare System (CAVHS) are made following the proper transporting protocol and that the standard classification to identify radiation limits established by the Department of Transportation and the Nuclear Regulatory Commission are met.
3. The contractor shall be (or use) a compounding pharmacy that is licensed by the State Board of Pharmacy in which it is located, and which is in good standing (no actions pending or unresolved such as a probationary period).
4. The contractor shall ensure that all transporting personnel have proper identification and documents when delivering supplies to CAVHS.
5. The contractor shall establish a method to hand-off to the appropriate Nuclear Medicine personnel during delivery.
6. The contractor shall ensure that all containers delivered to CAVHS are sealed appropriately to ensure that the package has not been compromised during transportation.
7. The contractor shall pick up WBC scans within 1 hour of notification and shall return the tagged blood to CAVHS within 3 hours of time of pick-up.
8. The contractor shall ensure that samples are correctly labeled with patient identifiers when picked up and validated upon delivery of the tagged product.
9. The contractor shall ensure that all counts of drugs be correct on delivery, with no more than five errors per year.
10. The contractor shall deliver all products at no additional charge during normal business hours.
11. For all products, the contractor shall provide non-HEU options to the maximum extent possible. HEU products shall only be delivered when non-HEU products either do not exist or are temporarily unavailable.
Items listed are estimated quantities per year
Item #
Description
Estimated qty/year
Manufacturer
Country of Origin
1
Tc-99m Sestamibi UD
3500
2
Tc-99m NaTcO4 UD mCi ( Unit_Dose )
175
3
Tc-99m Non-HEU NaTcO4 MD
1600
4
Tc-99m Sulfur Colloid UD
100
5
Tc-99m Mebrofenin UD
75
6
Tc-99m Medronate UD
540
7
Tc-99m Pentetate UD ( Aerosol )
2
8
Tc-99m Pentetate UD ( Non_Aerosol )
2
9
Tc-99m Exametazime/ Ceretec WBCs
15
10
Tc-99m Exametazime UD
4
11
Tc-99m Macro Aggregated Albumin
45
12
Tc-99m Mertiatide UD
50
13
Tc-99mOxidronate UD
5
14
Ga-67 Gallium Citrate UD
2
15
I-123 Iobenguane Sulfate UD
2
16
I-123 USP NaI 200 uCi Cap
25
17
I-131 USP NaI DX Cap mCi ( Base )
30
18
I-131 USP NaI TX Cap ( Base )
12
19
I-131 USP NaI TX Cap (each addt'l mCi) ( mCi )
1500
20
In-111 Pentetate SDV/Vial
3
21
In-111 Pentetreotide UD
3
22
In-111 Autologous WBC Suspension
33
23
Sincalide Vial (CCK)
2
24
Tl-201 Thallous Chloride UD
3
25
UltraTag Vial
38
26
Tc-99m Pyrophosphate UD
30
27
In-111 WBC Bld Kit (Heparin&Hetastarch)
38
28
Tc-99m WBC Bld Kit (Heparin & Hetastarch)
25
29
In-111 Oxyquinoline MD
3
30
Xe-133 Xenon Gas 20 mCi Vial
5
31
Xe-133 Xenon Gas 10 mCi Vial
5
32
Y-90 Waste Containers (Nalgene Container 2L-case of 6)
8
33
Technetium Tc99m Tilmanocept Lymphoseek Study Dose
20
34
I-123 Ioflupane UD (Curium)
24
35
After Hours Callout
2
36
After Hours Delivery Charge
2

Â
This notice is to assist in determining potential sources only. Adequate information shall be provided for the Government to determine Contractors ability to provide the required radiopharmaceutical supplies at the time of Contractor s response to this notice. There is no solicitation currently available. There is no guarantee, expressed or implicit, that the market research for this acquisition will result in a particular set-aside, sole source award or any other guarantee of award strategy. All information is to be provided on a voluntary basis and at no charge to the Government.Â
Â

Attachments/Links